Bacillus ClausiiBacillus Clausii

 

 

Studies:

Invitro Studies

  • Few Bacillus groups are recognized as being safe to get cultures out of that is why only a few Bacillus strains are available for commercial use with humans
  • Invitro studies reveal that B Claussi can be grown at high salt levels, survive in high bile acids and survive hard gastric conditions aswell as their ability to adhere to epithelial cells

First study –

Quick Summary – Recurring Respiratory infection 80 children, 40 placebo, 2 billion spores per 5ml per day 3 months, result 3 day reduction in symptoms vs placebo

  • Probiotic milk before showed reduced respiratory infections in children so this study was launched
  • Suggested that intestinal microflora plays a large role in the maturation of the immune system
  • To work probiotics must be able to overcome gastric acidity and colonize the intestine B claussi is a probiotic shown to be able to do this and even go through with the presence of antibiotics
  • They must also stick to the intestinal walls to potentiate the local immune system response
  • It has been demonstrated in previous studies that Bascillus Claussi is a probiotic capable of stimulating the immune response
  • 80 children with recurrent respiratory infections were chosen
  • 40 were in placebo group
  • 40 given probiotic of 2 billion spores per 5ml per day
  • Children examined every month for 3 months which was the treatment period
  • Children in the probiotic bacillus clausii group had 11.7 days duration of respiratory infection vs placebo group with 14.37
  • Also during follow up after the follow 3 months recurrent infections were also significantly reduced
  • Basically showed a 3 day reduction in symptoms, a significant result

Second Study

  • 27 patients suffering from acute diarrhea were studied with 3 loose stool motions iwthin 24 hours and more than 7 days
  • Patients received one capsul of b claussii with 2 billion units two times a day for 10 days
  • Tested on day 1, 3, 6 and 10
  • Duration of diarrhea decreased for 34.81 to 9.26 min per day and the frequency of defecation decreased from 6.96 to 1.78 times per day. Abdominal pain decreased from 3.22 severe to 0.74 absent and stool consistency improved from 3.93 watery to 1.22 soft.
  • Study indicated the b clausii strain was effective at alleviating the symptoms of diarrhea without side effects

Third study

  • One hundred and twenty H pylori positive patients randomly screened to receive 7 day triple therapy with rabeprazole 20mg, clarithromycin 500mg and amoxicillin 1gbd and b clausii tds each preperations containing 2 billion units for 14 days starting from first day of treatment. Another group was given the same triple therapy and a placebo for 14 days. It was found that the amount of nausea, diarrhea and gastric pain in patients treated with b clausii was much lower than that in the placebo group
  • Was found to be a great combat to the biggest side effect in h pylori antibiotic therapy which was nausea, diarrhea and gastric pain

Fourth Study

  • In a study in kenya it was seen that when B Clausii was given to children under five 2 billion per vial twice daily was administered to 90 children
  • Duration of diarrhea in b clause group was shorter 77.59 hours vs 86.74 hours. On day three there was a significant decrease in the mean number of diarrhea motions from 2.74 to 3.8 in placebo and day 4 1.45 to 2.35 in placebo. There was no significant ifferent in duration of hospital stay between the two groups

Fifth Study

  • A study in indea of children suffering from actue diarrhea at a hospital was done with 131 children divided into 2 groups one group with oral rehydration therapy zinc+ b clausii and group 2 comprised of children on ort and zin
  • The b clausii group diarrhea compared 22.64 hours with the placebo of 47 hours also hospital stay reduced from 2.78 days to 4.30 days in placebo